Title:In Silico Drug Design: Development of New Pyrimidine-based Benzothiazole Derivatives, Selective for CDK2
Volume: 18
Issue: 10
Author(s): Rania Kasmi*, Larbi Elmchichi, Abdellah El Aissouq, Mohammed Bouachrine and Abdelkrim Ouammou
Affiliation:
- Faculty of Science, Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez,Morocco
Keywords:
CoMFA, CoMSIA, molecular docking, CDK2, pyrimidine-based benzothiazole, 3D-QSAR.
Abstract:
Background: Kinases are proteins that control many biological functions. They are involved
in cellular regulation, and many of them are deregulated in cancer proliferation. The evidence of this
deregulation in many pathologies served as the origin of kinases as a therapeutic class and constitutes
the motive that leads numerous teams to search for inhibitors of these targets.
Objective: Based on 3D-QSAR studies and the molecular docking approach, we have developed new
potential inhibitors that could be optimized and transformed into colon cancer drugs.
Methods: To design new bioactive molecules and study their interactions with the cyclin-dependent
kinase type 2 (CDK2) enzyme, we used two virtual screening methods: 3D-QSAR modeling and molecular
docking on a series of 28 pyrimidine-based benzothiazole derivatives.
Results: To develop the model (3D QSAR), we used CoMFA and CoMSIA techniques using SYBYLX2.0
molecular modeling software. The statistical parameters reveal that the good CoMFA model displays
Q² = 0.587 and R²= 0.895 and CoMSIA displays Q² = 0.552 and R² = 0.768), which are considered
to be very good internal prediction values, while an external validation of a test series of 5 compounds
not included in the model development series gives R² test values of 0.56 for CoMFA and R² t
est values of 0.51 for CoMSIA. The molecular docking approach with AutoDock Tools-1.5.6 is introduced
in this work to enrich the interpretations extracted from the CoMFA and CoMSIA contour maps
and to provide an in silico research method for the most favorable mode of interaction of an inhibitor
within its receptor (CDK2).
Conclusion: We have constructed and validated a quantitative 3D model of structure-activity relationships
of pyrimidine-based benzothiazole derivatives as CDK2 inhibitors. This model allows us to identify
the nature and position of the groups that enhance the activity, giving us directions to discover new,
more powerful molecules in a limited time.
